The Association of Cardiac Structure and Function with Incident Stroke in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT and PARAGON-HF Trials
Abstract Body (Do not enter title and authors here): Backgrounds: Stroke is a major complication in patients with heart failure with preserved ejection fraction (HFpEF), associated with significant morbidity and mortality. However, predictors of incident stroke in this population remain insufficiently characterized. Echocardiographic assessment of cardiac structure and function may serve as a valuable tool for stroke risk stratification in patients with HFpEF. Research question: Which echocardiographic parameters are associated with the risk of stroke in patients with HFpEF? Methods: We pooled data from the echocardiographic sub-studies of the TOPCAT and PARAGON-HF trials, which included patients with HF and a LVEF ≥45%. The primary outcome was the centrally adjudicated incident of all types of strokes. Baseline clinical characteristics and echocardiographic parameters were compared between patients with and without incident stroke. The association of individual echocardiographic parameters with incident stroke was assessed using multivariable Cox models, adjusting for the CHA2DS2-VASc score, AF, anticoagulant use, systolic blood pressure, body mass index, race, treatment arm, and trial cohort. Results: Among 1,751 patients (654 from TOPCAT and 1,097 from PARAGON-HF; mean age: 73±9 years, female: 51%, mean LVEF: 59±9%, AF: 54%), 71 experienced a stroke over a median follow-up of 3.0 years (rate of 1.4 per 100 patient-years). Patients who had a stroke during follow-up had a higher prevalence of prior stroke, hypertension, and peripheral artery disease at baseline (all p<0.05). After multivariable adjustment, greater LV mean wall thickness (adjusted HR: 1.45, 95% CI: 1.19-1.77 per 1 SD increase) and the presence of mitral annular calcification (MAC, adjusted HR: 1.92, 95% CI: 1.18-3.11) were independently associated with a higher risk of incident stroke (Figure). Conversely, other echocardiographic parameters, including LVEF, left atrial volume index, and left atrial strain, were not significant predictors of stroke. These findings were consistent irrespective of AF status, age, sex, prior stroke, anticoagulation use, and trial cohort (all intearaction P>0.05). Conclusion: In this large cohort including over 1,700 patients with HFpEF with extensively well-characterized cardiac structure and function, LV mean wall thickness and MAC were independently associated with a higher risk of stroke, adding mechanistic insight and highlighting their potential role in stroke risk stratification in this population.
Hamatani, Yasuhiro
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Desai, Akshay
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Shah, Amil
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
Hegde, Sheila
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
Pitt, Bertram
( University of Michigan School
, Ann Arbor
, Michigan
, United States
)
Mcmurray, John
( BHF CARDIOVASCULAR RESEARCH CENTRE
, Glasgow
, United Kingdom
)
Pfeffer, Marc
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Solomon, Scott
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Skali, Hicham
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Chang, Sheng Nan
( NTUH Yun Lin Branch
, Dou-Liou City, Yun-Lin
, Taiwan
)
Lu, Henri
( Lausanne University Hospital
, Lausanne
, Switzerland
)
Claggett, Brian
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Shin, Sung-hee
( Inha University Hospital
, Incheon
, Korea (the Republic of)
)
Santos, Angela
( Universidade Federal do Rio Grande do Sul
, Porto Alegre
, Brazil
)
Inciardi, Riccardo
( University of Brescia
, Brescia
, Italy
)
Kosztin, Annamaria
( Semmelweis University Heart and Vascular Center
, Budapest
, Hungary
)
Jering, Karola
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Author Disclosures:
Yasuhiro Hamatani:DO NOT have relevant financial relationships
| Akshay Desai:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Abbott:Past (completed)
; Consultant:River2Renal:Active (exists now)
; Consultant:Roche:Active (exists now)
; Consultant:Regeneron:Active (exists now)
; Consultant:New Amsterdam:Active (exists now)
; Consultant:Novartis:Past (completed)
; Consultant:Merck:Past (completed)
; Consultant:Medtronic:Past (completed)
; Consultant:Medpace:Active (exists now)
; Consultant:GlaxoSmithKline:Past (completed)
; Consultant:Endotronix:Active (exists now)
; Consultant:CVS:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Researcher:Biofourmis:Active (exists now)
; Consultant:Bayer:Active (exists now)
; Consultant:Axon Therapies:Past (completed)
; Consultant:Avidity Biopharma:Active (exists now)
; Consultant:AstraZeneca:Active (exists now)
; Consultant:Alnylam:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Research Funding (PI or named investigator):Novartis:Past (completed)
; Research Funding (PI or named investigator):Bayer:Active (exists now)
; Research Funding (PI or named investigator):AstraZeneca:Active (exists now)
; Research Funding (PI or named investigator):Alnylam:Active (exists now)
| Amil Shah:DO NOT have relevant financial relationships
| Sheila Hegde:No Answer
| Bertram Pitt:DO have relevant financial relationships
;
Consultant:Bayer:Active (exists now)
; Other (please indicate in the box next to the company name):Mineralys-DSMB:Active (exists now)
; Individual Stocks/Stock Options:Anacardio:Active (exists now)
; Individual Stocks/Stock Options:Sea star Medical:Active (exists now)
; Individual Stocks/Stock Options:Prointel:Active (exists now)
; Individual Stocks/Stock Options:Sarfez Pharmceuticals:Active (exists now)
; Individual Stocks/Stock Options:KBP Biosciences :Active (exists now)
; Individual Stocks/Stock Options:Cereno scientific:Active (exists now)
; Individual Stocks/Stock Options:G3 Pharmaceuticals:Active (exists now)
; Individual Stocks/Stock Options:SQ innovations :Active (exists now)
; Individual Stocks/Stock Options:Sc Pharmaceuticals:Active (exists now)
; Individual Stocks/Stock Options:Vifor:Active (exists now)
; Consultant:Bristol Myers squibb:Active (exists now)
; Consultant:Lexicon:Active (exists now)
; Consultant:Boehringer Ingelheim:Active (exists now)
| John McMurray:DO NOT have relevant financial relationships
| Marc Pfeffer:DO have relevant financial relationships
;
Consultant:Alexion:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Consultant:Novartis:Active (exists now)
; Consultant:Jazz:Past (completed)
; Consultant:Intellia:Active (exists now)
; Individual Stocks/Stock Options:DalCor:Active (exists now)
; Consultant:DalCor:Active (exists now)
; Consultant:AstraZeneca:Active (exists now)
| Scott Solomon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now)
; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, Askbio, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo, Synhale, Recordati:Active (exists now)
| Hicham Skali:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Cytokinetics:Active (exists now)
| Sheng Nan Chang:DO NOT have relevant financial relationships
| Henri Lu:DO have relevant financial relationships
;
Consultant:Cytokinetics:Past (completed)
; Consultant:Astra Zeneca:Past (completed)
; Advisor:Bayer:Past (completed)
| Brian Claggett:No Answer
| Sung-Hee Shin:DO NOT have relevant financial relationships
| Angela Santos:No Answer
| Riccardo Inciardi:DO NOT have relevant financial relationships
| Annamaria Kosztin:No Answer
| Karola Jering:DO have relevant financial relationships
;
Speaker:Alnylam Pharmaceutics:Active (exists now)